Literature DB >> 24603851

miR-7 inhibits glioblastoma growth by simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK pathways.

Zhenlin Liu1, Zhongmin Jiang2, Jianyong Huang3, Shuqiang Huang3, Yanxia Li4, Simiao Yu1, Shizhu Yu5, Xiaozhi Liu1.   

Abstract

Epidermal growth factor receptor (EGFR) signaling regulates glioblastoma cell proliferation, survival, migration and invasion and plays a key role in tumor progression. We show that microRNA-7 (miR-7) is a common regulator of the phosphoinositide-3-kinase (PI3K)/ATK and Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathways, both of which are launched by EGFR through its two direct targets, the transcription factors PI3K and Raf-1, respectively. Enforced expression of miR-7 markedly decreased expression of PI3K, phosphorylated Akt, Raf-1, phosphorylated MEK 1/2, and cyclin D1, as well as slightly reduced expression of EGFR. Forced expression of PI3K or Raf-1 transcripts lacking the 3'-untranslated region (3'-UTR) partially reversed the effects of miR-7 on cell growth inhibition and cell cycle arrest in glioma cells. Additionally, transient expression of miR-7 in glioblastoma cells strongly inhibited in vivo glioblastoma xenograft growth. We conclude that miR-7 is a potential tumor suppressor in glioblastoma that acts by targeting multiple oncogenes related to the downstream pathway of EGFR and may serve as a novel therapeutic target for malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24603851     DOI: 10.3892/ijo.2014.2322

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  57 in total

Review 1.  Targeting IGF1R pathway in cancer with microRNAs: How close are we?

Authors:  Arathy S Kumar; Suresh K Rayala; Ganesh Venkatraman
Journal:  RNA Biol       Date:  2018-02-01       Impact factor: 4.652

2.  Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis.

Authors:  Laura Foj; Xavier Filella
Journal:  Pathol Oncol Res       Date:  2018-10-26       Impact factor: 3.201

3.  Breviscapine suppresses the growth of non-small cell lung cancer by enhancing microRNA-7 expression.

Authors:  Jian Zeng; Shunv Cai
Journal:  J Biosci       Date:  2017-03       Impact factor: 1.826

4.  The Downregulation of MicroRNA-146a Modulates TGF-β Signaling Pathways Activity in Glioblastoma.

Authors:  Shunzeng Lv; Bowen Sun; Congxin Dai; Ranran Shi; Xingtong Zhou; Wenyuan Lv; Xiao Zhong; Renzhi Wang; Wenbin Ma
Journal:  Mol Neurobiol       Date:  2014-10-19       Impact factor: 5.590

Review 5.  Role of microRNA-7 in digestive system malignancy.

Authors:  Wan-Qun Chen; Ling Hu; Geng-Xin Chen; Hai-Xia Deng
Journal:  World J Gastrointest Oncol       Date:  2016-01-15

Review 6.  Circular RNA participates in the carcinogenesis and the malignant behavior of cancer.

Authors:  Zhen-Jun Zhao; Jun Shen
Journal:  RNA Biol       Date:  2015-12-09       Impact factor: 4.652

Review 7.  Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma.

Authors:  Wanli Yu; Sai Liang; Chunzhi Zhang
Journal:  Neuromolecular Med       Date:  2018-09-04       Impact factor: 3.843

8.  microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis.

Authors:  Deepak Bhere; Kaoru Tamura; Hiroaki Wakimoto; Sung Hugh Choi; Benjamin Purow; Jeremy Debatisse; Khalid Shah
Journal:  Neuro Oncol       Date:  2018-01-22       Impact factor: 12.300

9.  Elevated microRNA-7 inhibits proliferation and tumor angiogenesis and promotes apoptosis of gastric cancer cells via repression of Raf-1.

Authors:  Jing Lin; Zewa Liu; Shasha Liao; E Li; Xiaohua Wu; Wanting Zeng
Journal:  Cell Cycle       Date:  2020-09-15       Impact factor: 4.534

Review 10.  mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme.

Authors:  M Janaki Ramaiah; K Rohil Kumar
Journal:  Mol Biol Rep       Date:  2021-06-16       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.